183 related articles for article (PubMed ID: 19517064)
1. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.
Oh S; Ohlfest JR; Todhunter DA; Vallera VD; Hall WA; Chen H; Vallera DA
J Neurooncol; 2009 Dec; 95(3):331-342. PubMed ID: 19517064
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
3. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
5. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 Nov; 13(21):6486-93. PubMed ID: 17975161
[TBL] [Abstract][Full Text] [Related]
6. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Vallera DA; Stish BJ; Shu Y; Chen H; Saluja A; Buchsbaum DJ; Vickers SM
Gut; 2008 May; 57(5):634-41. PubMed ID: 18222985
[TBL] [Abstract][Full Text] [Related]
7. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
[TBL] [Abstract][Full Text] [Related]
8. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Vallera VD; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2007 Jan; 120(2):411-9. PubMed ID: 17075792
[TBL] [Abstract][Full Text] [Related]
9. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.
Oh S; Stish BJ; Vickers SM; Buchsbaum DJ; Saluja AK; Vallera DA
Pancreas; 2010 Aug; 39(6):913-22. PubMed ID: 20182395
[TBL] [Abstract][Full Text] [Related]
10. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
11. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
12. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
14. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts.
Ozawa T; Santos RA; Lamborn KR; Bauer WF; Koo MS; Kahl SB; Deen DF
Mol Pharm; 2004; 1(5):368-74. PubMed ID: 16026007
[TBL] [Abstract][Full Text] [Related]
16. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2006 May; 118(10):2594-601. PubMed ID: 16358262
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
[TBL] [Abstract][Full Text] [Related]
18. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Rustamzadeh E; Vallera DA; Todhunter DA; Low WC; Panoskaltsis-Mortari A; Hall WA
J Neurooncol; 2006 May; 77(3):257-66. PubMed ID: 16314943
[TBL] [Abstract][Full Text] [Related]
20. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Grahn AY; Bankiewicz KS; Dugich-Djordjevic M; Bringas JR; Hadaczek P; Johnson GA; Eastman S; Luz M
J Neurooncol; 2009 Nov; 95(2):185-197. PubMed ID: 19466380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
